Alvotech Lines Up FDA Inspection Ahead Of Adalimumab Action
Reinspection Of Reykjavik Plant Scheduled For 6 March, Ahead Of 13 April Goal Date
Alvotech has secured a US FDA reinspection of its Reykjavik plant in March, ahead of the agency’s April goal date for action on the firm’s pending application for a high-concentration, interchangeable adalimumab biosimilar rival to Humira.
